Viking Therapeutics, Inc. Income Statement
VKTX / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
Viking Therapeutics, Inc. reported $0 in revenue and $360M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $48.4M | $49.3M | $10.7M | $10.7M | $10.7M | $9.1M | $7.1M | $5.3M | $5.3M | $5.0M | $1.2M | $1.2M |
| R&D Expense | $345.0M | $101.6M | $45.0M | $45.0M | $31.9M | $23.6M | $19.0M | $13.7M | $13.7M | $7.0M | $22.2M | $22.2M |
| Operating Income | -$393.3M | -$150.9M | -$55.7M | -$55.7M | -$42.7M | -$32.7M | -$26.2M | -$19.1M | -$19.1M | -$12.0M | -$23.5M | -$23.5M |
| Income Tax | $1.0K | $1.0K | $2.0K | $2.0K | $0 | $0 | $0 | $0 | $0 | - | - | - |
| Net Income | -$359.6M | -$110.0M | -$55.0M | -$55.0M | -$39.5M | -$25.8M | -$22.1M | -$20.6M | -$20.6M | -$23.4M | -$21.9M | -$21.9M |
| EPS (Basic) | -$0.91 | -$0.90 | -$0.71 | -$0.71 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$0.91 | -$0.90 | -$0.71 | -$0.71 | -$0.54 | -$0.36 | -$0.38 | -$0.79 | -$0.90 | -$3.68 | -$5.23 | - |
| Shares Outstanding | 111.6M | 100.1M | 78.3M | 78.2M | 73.2M | 72.4M | 71.7M | 35.8M | 20.8M | 9.7M | 6.0M | 4.2M |